CytoCore, Inc. Poised at Leading-Edge of Projected $92 Billion Molecular Diagnostics Market.New Market Analysis Finds 41 Percent Annual Growth in Major World Markets CHICAGO -- Currently ramping up for Q2 production and distribution of its suite of products for the early screening and treatment of reproductive cancers, CytoCore, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYCR) today noted a comprehensive new market report projecting 41 percent annual growth in the area of molecular diagnostics and screening in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. alone, with a market potential of $92 billion projected by 2016. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the newly released Kalorama Information report, "Molecular Diagnostics: Major World Markets," the pharmacogentic sector is especially well-positioned to "skyrocket" from its current $3-plus billion in revenue to more than $60 billion by 2016, with cancer tests and treatments factoring "heavily" into this market growth. The primary market drivers will be the development of new high-volume tests with the introduction of new instrumentation which will provide greater ease, speed and quality in performing these tests. "The whole area of molecular diagnostics and screening is exploding and CytoCore has strategically secured a place at the front of the pack in terms of identifying biomarkers and developing innovative medical devices aimed at catching deadly uterine uterine /uter·ine/ (u´ter-in) pertaining to the uterus. u·ter·ine adj. Of, relating to, or in the region of the uterus. , cervical and endometrial cancers at their earliest stages," said Dr. Augusto Ocana, chief executive officer at the late-stage bio-medical research company. "We understand the enormous potential and need for cutting-edge diagnostics in this worldwide market." With trials currently underway and plans to begin Q2 manufacturing and distribution of its FDA-approved e2 Collector[TM] for the improved retrieval of cervical sample cells, CytoCore has also identified and patented the highly sensitive Adj. 1. highly sensitive - readily affected by various agents; "a highly sensitive explosive is easily exploded by a shock"; "a sensitive colloid is readily coagulated" and accurate P2X7 biomarker associated with early detection of cancer in epithelial cells Epithelial cells Cells that form a thin surface coating on the outside of a body structure. Mentioned in: Corneal Transplantation in the uterus, cervix cervix /cer·vix/ (ser´viks) pl. cer´vices [L.] 1. neck. 2. the front portion of the neck. 3. cervix uteri. and bladder. The Company also has in Phase I clinical trials a unique new uterine cancer uterine cancer Malignant tumour of the uterus. Cancers affecting the lining of the uterus (endometrium) are the most common cancers of the female reproductive tract. screening test based on the P2X7 biomarker. CytoCore additionally plans to have its automated image guided microscopy platform ready for trials with the Pap test Pap test, Pap smear, or Papanicolaou test (păp'ənē`kəlou), medical procedure used to detect cancer of the uterine cervix. later this year, and available for partnering with other bio-markers in need of a high-speed automated testing platform. For further information about the e2Collector and CytoCore's full suite of products for the early screening, diagnoses and treatment of reproductive cancers, visit www.CytoCoreInc.com. More information about Kalorama Information's "Molecular Diagnostics: Major World Markets" is available at www.kaloramainformation.com/Molecular-Diagnostics-Major-1365888. It is also available at MarketResearch.com. Kalorama is a division of MarketResearch.com. About CytoCore, Inc. CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial endometrial /en·do·me·tri·al/ (en?do-me´tre-il) pertaining to the endometrium. endometrial, n relating to the end-ometrium or cavity of the uterus. , and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion